Aardoom MA, Kemos P, Tindemans I, Aloi M, Koletzko S, Levine A, Turner D, Veereman G et al.(2020). International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study. BMJ Open vol. 10, (7)
Papachristos A, Kemos P, Kalofonos H, Sivolapenko G(2020). Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer. Oncologist
Costes L, Tindemans I, Joosse ME, Aardoom MA, Jongsma MME, Raatgeep RHC, van Haaften DH, Alexander KL et al. (2020). IgG responses to multiple bacterial flagellins identify a subgroup of paediatric therapynaive Crohn's disease patients with increased microbiota-specific T-cell reactivity. JOURNAL OF CROHNS & COLITIS. vol. 14, S046-S046.
Aardoom M, Kemos P, Ruemmele FM, van Ommen CH, Croft NM, de Ridder L, PIBDnet P-SC (2020). The occurrence of venous thromboembolisms in paediatric-onset IBD. JOURNAL OF CROHNS & COLITIS. vol. 14, S194-S194.
Papachristos A, Kemos P, Katsila T, Panoilia E, Patrinos GP, Kalofonos H, Sivolapenko GB(2019). Vegf-a and icam-1 gene polymorphisms as predictors of clinical outcome to first-line bevacizumab-based treatment in metastatic colorectal cancer. International Journal of Molecular Sciences vol. 20, (22)
Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D et al.(2019). The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Alimentary Pharmacology and Therapeutics vol. 50, (2) 204-214.
Rao A, Kemos P, Kamperidis N, Naik S, Croft NM, Sanderson I (2019). CHILDREN WITH CROHN'S DISEASE WHO RESPOND TO AN ENTERAL DIET ARE TWICE AS LIKELY TO REMAIN IN CLINICAL REMISSION OVER 5 YEARS. GASTROENTEROLOGY. vol. 156, S615-S616.
Mecci J, Maxan M-E, Kemos P, Telfer P, Barroso F, Foster G, Banu K (2019). Diagnosis of sickle cell liver disease may be aided by non-invasive tests. JOURNAL OF HEPATOLOGY. vol. 70, E586-E587.
Waller K, Versteeg-de Jong A, Li W, Lowe R, Kemos P, Syn W-K, Alazawi W (2019). Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight. JOURNAL OF HEPATOLOGY. vol. 70, E551-E552.
Aardoom MA, Kemos P, Ruemmele F, Tindemans I, Samsom JN, Croft N, de Ridder L, PIBDnet PIBDSC (2019). A global prospective observational study in children and adolescents with paediatric-onset IBD: the PIBD-SETQuality inception cohort. JOURNAL OF CROHNS & COLITIS. vol. 13, S171-S172.
Aardoom MA, Kemos P, Ruemmele F, Croft N, de Ridder L, PIB PSC (2019). An ongoing safety registry to identify rare and severe complications in children with paediatric-onset IBD. JOURNAL OF CROHNS & COLITIS. vol. 13, S413-S413.
Dolman G, Saleh H, Kemos P, Kennedy PTF (2018). Quantitative Hepatitis B Surface Antigen (qHBsAg) Has Poor Performance As a Marker of High Risk Antenatal Chronic Hepatitis B (CHB) in a Multi-Ethnic Population. HEPATOLOGY. vol. 68, 1187A-1188A.
Joosse ME, Aardoom MA, Kemos P, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL et al.(2018). Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN. Alimentary Pharmacology and Therapeutics vol. 48, (5) 523-537.
De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM et al.(2018). Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of south asian descent. Frontline Gastroenterology vol. 9, (2) 115-121.
Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R et al.(2018). Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet Neurology vol. 17, (3) 213-222.
Kemos P, Aardoom M, Ruemmele F, de Ridder L, Croft N (2018). Designing the first pan-European paediatric IBD database to allow the study of incidence and prevalence of UC, CD, and their rare and severe complications. JOURNAL OF CROHNS & COLITIS. vol. 12, S508-S508.
Aardoom M, Kemos P, Ruemmele F, Croft N, de Ridder L, PIBD PSC (2018). Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnet. JOURNAL OF CROHNS & COLITIS. vol. 12, S403-S404.
Alazawi W, Bernabe E, Tai D, Janicki T, Kemos P, Samsuddin S, Syn W-K, Gillam D et al.(2017). Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. PLoS One vol. 12, (12) e0185902-e0185902.
De Silva S, Li W, Kemos P, Brindley J, Mecci J, Samsuddin S, Chin-Aleong J, Feakins R et al. (2017). NON-INVASIVE MARKERS OF LIVER FIBROSIS IN FATTY LIVER DISEASE ARE UNRELIABLE IN PEOPLE OF SOUTH ASIAN DESCENT. GUT. vol. 66, A164-A164.
De Silva S, Li W, Kemos P, Brindley JH, Feakins R, Chinaleong J, Samsuddin S, Foster GR et al. (2017). Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity. JOURNAL OF HEPATOLOGY. vol. 66, S595-S596.
Alazawi W, Tai DF, Kemos P, Bernabe E, Janicki T, Gillam D, Samsuddin S, Syn WK et al. (2017). Periodontitis is strongly associated with NAFLD in the NHANES III cohort and in an independent prospective study, is more common in those with biopsy-proven advanced compared to mild liver disease. JOURNAL OF HEPATOLOGY. vol. 66, S596-S596.